Ask AI

Breast Cancer

For coverage of lymphoma and leukemia at ASCO and EHA 2026, click here.

Share

Program Content

Activities

  • PIKALO 1
    PIKALO-1: Phase I/II Study of Tersolisib + Endocrine Therapy ± CDK4/6 Inhibitors in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 24, 2026

  • ASCENT 04 PFS2
    ASCENT-04/KEYNOTE-D19: PFS2 With 1L Sacituzumab Govitecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in PD-L1–Positive Advanced TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 26, 2026

  • ASCENT 03 PFS2
    ASCENT-03: PFS2 and Subsequent Therapies With 1L Sacituzumab Govitecan vs Chemotherapy in Metastatic TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 26, 2026

  • Elacestrant Plus Capivasertib
    ELEVATE Phase Ib/II Umbrella Study: Elacestrant Plus Capivasertib in Patients With Previously Treated ER+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 26, 2026

  • SERENA 6 Update
    SERENA-6 Update: Switch to Camizestrant With Continued CDK4/6 Inhibitor for Emergent ESR1 Mutations in ER+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 30, 2026

  • TROPION Breast02 PFS2
    TROPION-Breast02: PFS2 and Additional Efficacy Outcomes With 1L Dato-DXd vs Chemotherapy in Advanced TNBC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 30, 2026

  • NATALEE
    NATALEE: Prognostic and Predictive Outcomes by Baseline Gene Expression in Patients Treated With Ribociclib + NSAI for HR+/HER2- Early Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 07, 2026

  • OPTIMA
    OPTIMA: Phase III Noninferiority Trial of Gene Expression–Directed Chemotherapy in Patients With High-Risk ER+/HER2- Early Breast Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 07, 2026

Supporters

This activity is supported by educational grants from Lilly and Stemline Therapeutics, Inc.

Lilly

Stemline Therapeutics, Inc.